Loading…
Employees: 3,114
Size Cisen Pharmaceutical (603367.SS) is a China Health Care company (Medical Specialties) with a market value of $890M, the 2539th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.27 on 6 Nov 2026.
Performance Over six months the shares fell 14.7%, against -13.9% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 6.4% over the last twelve months (peer median +11.1%); the operating margin is 8.2% (peer median 12.2%).
Valuation It trades at 8.3× forward earnings against a peer median of 21.4× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.9 points above its cost of capital (6.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.34B | CN¥3.42B | CN¥3.95B | CN¥4.42B | CN¥4.03B |
| Revenue growth | — | -14% | -11% | +10% | — |
| Gross profit | CN¥1.83B | CN¥1.66B | CN¥2.09B | CN¥2.46B | CN¥2.14B |
| EBITDA | n/a | CN¥458M | CN¥639M | CN¥749M | CN¥522M |
| Net income | CN¥387M | CN¥421M | CN¥509M | CN¥521M | CN¥350M |
| Free cash flow | CN¥578M | CN¥555M | CN¥533M | CN¥480M | CN¥259M |
| Capital expenditure | CN¥8.59M | CN¥64.8M | CN¥102M | CN¥17.7M | CN¥35.2M |
| Total debt | CN¥252M | CN¥399M | CN¥576M | CN¥529M | CN¥478M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603367.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.1% | -5.2% | 8th lowest of 21 |
| 6-month return | -14.7% | -13.9% | 11th highest of 21 |
| Distance from 52-week high | -43.5% | -34.0% | 7th lowest of 21 |
| Revenue growth (TTM) | -6.4% | +11.1% | 4th lowest of 21 |
| Operating margin | 8.2% | 12.2% | 5th lowest of 21 |
| Forward P/E | 8.3× | 21.4× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -12.9% | 6.2% | least demanding of 17 |
| Growth delivered (Del g) | -1.3% | +11.9% | 2nd lowest of 17 |
| Hurdle (Req g minus delivered) | -11.7 pp | -4.3 pp | 6th least demanding of 17 |
| ROIC minus cost of capital | +3.9 pp | +1.9 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 15.9× | 5.5% | +105.8% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | n/a | n/a | n/a |